Company Overview and News
Can't believe it has been this long since I made a stock purchase. The last purchase I made was AT&T (NYSE:T) back in June. It has been at least 4 months and my portfolio has been feeling a little neglected. But at least in all that time, it was still working hard for me and bringing in some quality dividends. I just recently surpassed my dividends collected for all of last year.
T BNS BNS
2018-10-13 seekingalpha - 1
Welcome back! September has historically been a slow month for dividend raises, and this year was no exception. The good news is that the fall is expected to see plenty of action. It all starts this week as there is one Canadian Dividend All-Star which is expected to announce its annual dividend raise. Before we get into that, there is plenty to catch up on from the past few weeks. Of note, all figures are in Canadian dollars unless otherwise noted.
TRI CWB BNS SIS FTS TRI SISXF FTS CBWBF BNS
2018-10-05 seekingalpha - 1
This is the third quarter review of my retirement income portfolio. It was a very active quarter that included a final pension rollover to my IRA. About half of the rollover funds have been deployed. Some existing positions were trimmed to take profit and to diversify. In recent weeks, I've written articles about the 19 new positions, so this review will be a brief summary.
TXN CNUTF XOM RDSB ENB OPRF RDSA FTS WMT BCE CSCO ABBV DUKH BAMGF SO UPS MAIN TYT KMB CMI ENB MFC RY 0945 BNS JNJ ITW RYDBF 7203 WPC SPG ABBV MSFT QCOM PFE CLX CDUAF BAMKF NNN SOJA TM ADP SKT EPD TD ETN BNS MSCA AAPL BIP RYDAF TD CSCOI BAM BEP CU VTR IBM RDS.B RY RDS.A TNTTF APLE O DUK FDX TOYOF MSCA.CL BLK HP PEP ADPVV FTS PPL MFC
This is the sixth month I have officially tracked dividend income (in an article) for Jane's Traditional and Roth IRA Accounts. Her dividend income totaled $689.45.
GIS WBA ENB OPRF WMB SCHF JCI HSY ABBV MMM POL MO DUKH GD BAC TRV GILD MAIN CMI ENB RY BNS JNJ ITW VZ WPC ABBV MSFT ADM PFE PM PFBC IRET CTL OXLCM OXLCO TD ETN OXLCN BNS BAC MSCA INTC TD IBM RY TNTTF LYB MSB O DUK SNX OXLC IRM MSCA.CL EMRAF AFL ORI PPL
2018-09-22 seekingalpha - 1
Together with its Canadian peers, it is a core holding in my dividend growth portfolio and one I will substantially increase over the years.
BAC C RY TNTTF BMO TD BNS BAC BMO RY BNS JPM TD
Chicago, IL – September 4, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Royal Bank of Canada (RY - Free Report) , Bank of Montreal (BMO - Free Report) and The Bank of Nova Scotia (BNS - Free Report) .
BMO BMQZF RBBN NWL RY RY BNS BMO AMD BNS
The Toronto-Dominion Bank’s (TD - Free Report) third-quarter fiscal 2018 (ended Jul 31) adjusted earnings came in at C$1.66 per share, up 10% year over year. Also, adjusted net income rose 9% to C$3.13 billion ($2.40 billion). Improvement in revenues reflects higher interest rates and growth in the bank’s U.S. retail business. Also, strong capital and profitability ratios, as well as loan and deposit growth remained impressive.
BMO TNTTF BNS SCVL BMO TD TD BNS PAYC
Key foreign banks released earnings results in the last two weeks, providing a better understanding of the industry’s near-term prospects. After focusing on the one-time U.S. tax charges in the first half of this year, foreign banks shifted attention to the Fed’s “gradual” rate hike decision.
BMO BMQZF RY RY BNS BMO BNS
The Bank of Nova Scotia (BNS - Free Report) reported third-quarter fiscal 2018 (ended Jul 31) results before the opening bell. Adjusted net income for the quarter came in at C$2.3 billion ($1.8 billion), up 7% year over year. Results exclude acquisition-related costs. A rise in revenues and fall in provisions largely drove improvement in results, which was partially offset by elevated expenses. Improvement in capital and profitability ratios was impressive.
DB BNS UBS URBN PBB PSEC BNS
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to TSX:BNS / Bank of Nova Scotia on message board site Silicon Investor.
|Bank of Nova Scotia Split||Bank of Nova Scotia Split||Bank of Nova Scotia Split|